Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iridex Corporation (IRIX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer incorporated in Delaware with principal offices in Mountain View, California, Iridex uses SEC reports to present information on its ophthalmic laser business, financial condition, and material events.
Key documents for IRIX include Form 10‑K annual reports, which describe the company’s business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for glaucoma, diabetic macular edema (DME), and other retinal diseases. Form 10‑Q quarterly reports provide interim updates on revenues from consoles, delivery devices, consumables, services, and support activities, along with segment information for its ophthalmology operations.
Iridex also files Form 8‑K current reports to announce specific events. Recent 8‑Ks have covered preliminary financial results, quarterly earnings releases, participation in investor conferences, and Nasdaq listing compliance matters, including the company’s notification of non‑compliance with Listing Rule 5550(b) and subsequent confirmation that it regained compliance with the stockholders’ equity requirement.
Investors can further review registration statements, proxy materials, and insider transaction reports such as Form 4, where applicable, to understand equity ownership and governance. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non‑GAAP adjusted EBITDA reconciliations, stockholders’ equity, and risk factor disclosures, allowing users to navigate Iridex’s regulatory history more efficiently.
Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.
Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.
Iridex Corp (IRIX) Form 4: Romeo R. Dizon, identified as the Chief Financial Officer, reported three transactions on 09/04/2025. The filing shows acquisitions of 404, 96, and 625 common shares at prices of $1.32, $1.345, and $1.39 respectively. After those transactions the filing lists beneficial ownership totals of 54,029, 54,125, and 54,750 shares. The form was signed by an attorney-in-fact on 09/05/2025.
Iridex Corp (IRIX) insider filing shows Chief Financial Officer Romeo R. Dizon, via attorney-in-fact, purchased 625 shares of common stock on 09/03/2025 at $1.36 per share, bringing his beneficial ownership to 53,625 shares.
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported a purchase of 625 shares of the company's common stock on 09/02/2025 at a price of $1.34 per share, increasing his beneficial ownership to 53,000 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing documents a routine insider purchase by a named officer and identifies no derivative transactions or additional disclosures.
Iridex Corp (IRIX) Form 4: The reporting person, Romeo R. Dizon (CFO), made a purchase of 625 shares of Iridex common stock on 08/29/2025 at a price of $1.37 per share. Following the transaction, Mr. Dizon beneficially owned 52,375 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported multiple open-market purchases totaling 1,005 shares on 08/28/2025. The transactions executed at prices between $1.325 and $1.36 per share increased his direct beneficial ownership from 50,745 shares to 51,750 shares. Individual purchases reported: 50 shares at $1.33, 200 shares at $1.325, 250 shares at $1.35 and 505 shares at $1.36. The Form 4 was signed by an attorney-in-fact on 08/29/2025. No derivative transactions were reported and no additional explanatory text was provided.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
